Blog
About

1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF V600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          EGFR-T790M and BRAF V600E are the common resistance mechanisms to EGFR-tyrosine kinase inhibitors (TKIs). Standard treatment for the triple mutations of EGFR-19del, T790M, and BRAF V600E is still under debate. Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable progression-free survival of 9 months without any serious adverse reaction. At the progression of the disease, C797S mutation in cis was detected by liquid biopsy. Subsequently, brigatinib with cetuximab was administered but no curative effect was observed. Then, therapy was changed to apatinib combined with osimertinib. The subsequent CT scan showed that the lesions reached stable disease (SD), and the survival benefit has been evaluated. This case showed that the combination treatment of osimertinib and dabrafenib plus trametinib might be a great treatment option for NSCLC patients with triple mutations ( EGFR-19del/T790M/BRAFV600E).

          Related collections

          Most cited references 8

          • Record: found
          • Abstract: not found
          • Article: not found

          Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              LBA11Defining the lethal subclone in metastatic lung cancer

                Bookmark

                Author and article information

                Journal
                Onco Targets Ther
                Onco Targets Ther
                ott
                ott
                OncoTargets and therapy
                Dove
                1178-6930
                10 August 2020
                2020
                : 13
                : 7933-7939
                Affiliations
                [1 ]Guangzhou University of Chinese Medicine , Guangzhou, People’s Republic of China
                [2 ]Shenzhen Hospital of Guangzhou University of Chinese Medicine , Shenzhen, People’s Republic of China
                [3 ]Mygene Medical Technology , Guangzhou, People’s Republic of China
                [4 ]Department of Cancer Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine , Guangzhou, People’s Republic of China
                Author notes
                Correspondence: Zhanhua Liu Email lzh065@163.com
                [*]

                These authors contributed equally to this work

                Article
                240775
                10.2147/OTT.S240775
                7428409
                © 2020 Ding et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                Page count
                Figures: 5, References: 16, Pages: 7
                Funding
                Funded by: Natural Science Foundation of Guangdong, open-funder-registry 10.13039/501100003453;
                Award ID: 2017A030313731
                This research was funded by Natural Science Foundation of Guangdong province China: 2017A030313731.
                Categories
                Case Report

                Oncology & Radiotherapy

                combination therapy, egfr-19del, egfr tki, brafv600e, t790m

                Comments

                Comment on this article